Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42%
Tap title to read story
A late‑stage trial of Moderna and Merck’s melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda, reduced the relative risk of disease recurrence or death by 42% compared with Keytruda alone after a median follow‑up of 24.6 months. The result, disclosed ahead of the European Society for Medical Oncology meeting, met the study’s primary endpoint and was described by analysts as a landmark moment. Shares of both companies fell immediately, with Moderna’s stock dropping nearly 25% and Merck’s falling about 1%. Analysts noted a “sell‑the‑news” reaction to the announcement. The 42% reduction is slightly below the 44% observed in a smaller Phase 2 trial, but still represents a significant clinical benefit.
More context
Timeline
- 2026-08 — Moderna and Merck announce melanoma vaccine trial results
- On October 22 2026 Data leak triggers immediate share decline.
- On October 22 2026 Merck shares fall by one percent.
- On October 22 2026 Moderna shares tumble by twenty‑five percent.
Why it matters
Immediate US impact: Investors react with sharp sell‑off Possible long-term US impact: Potential for future revenue growth Most affected groups: Pharmaceutical investors and oncology patients Reader priority: Understand vaccine efficacy and market response
Coverage notes
Center: Coverage from Reuters, Ars Technica, Scientific American frames this as a developing news story: Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42%. Reporting emphasizes verified facts, named sources, and near-term impact for readers. Left: Left-leaning desks covering the same development typically emphasize public impact, institutional accountability, and who is most affected. Right: Right-leaning desks covering the same development typically emphasize practical outcomes, market or security stakes, and institutional response.
Primary report
BioPharma Dive — Moderna‑Merck Melanoma Vaccine Cuts Relapse Risk by 42%
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.

































